Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.

Also called NCT04030546

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 128 participants (planned count) (from the registry)
Sponsor
Vilnius University (from the registry)
Registry
  • NCT NCT04030546
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Lithuania (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04030546. Randomized; single masking; primary purpose treatment. Start 2019-06-01 (actual); primary completion 2020-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
Condition
Patients With Cancer
Intervention (Drug)
Ivabradine
Lead sponsor
Vilnius University (class: other)

Record details

Record id
cardio:ct-nct04030546
Content hash
e5f29e71eb8969ad1817f7088376b2a0920473fad98d099364a15dc715be11c9